Map** of catecholaminergic denervation, neurodegeneration, and inflammation in 6-OHDA-treated Parkinson's disease mice

M Santoro, RK Lam, SE Blumenfeld, W Tan… - npj Parkinson's …, 2025 - nature.com
Efforts to develop disease-modifying treatments for Parkinson's disease (PD) have been
hindered by the lack of animal models replicating all hallmarks of PD and the insufficient …

Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study

MO Khrieba, SK Hegazy, W Mustafa… - …, 2024 - Springer
Background The clinical presentations of Parkinson's disease (PD), a chronic
neurodegenerative condition, include bradykinesia, hypokinesia, stiffness, resting tremor …

[HTML][HTML] Investigation of the anxiolytic effects of calcium channel-blocker, nifedipine, and beta-blocker, propranolol

E Wahsh, TM Ibrahim… - Vogel conflict rat model …, 2024 - researcherslinks.com
Anxiety is a common psychiatric disorder, which is widely treated by the addicting
substances benzodiazepines. The major objective of the current study is to explore …